Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling. (December 2020)

• Record Type: Journal Article
• Authors: Steelman, Linda S.; Chappell, William H.; Akula, Shaw M.; Abrams, Stephen L.; Cocco, Lucio; Manzoli, Lucia; Ratti, Stefano; Martelli, Alberto M.; Montalto, Giuseppe; Cervello, Melchiorre; Libra, Massimo; Candido, Saverio; McCubrey, James A.
• Is Part Of: Advances in biological regulation. Volume 78(2020)
• Publication Date: 2020-12
• Subjects: EGFR -- EGFRvIII -- V-Erb-B -- Breast cancer -- Drug resistance; Cellular control mechanisms -- Periodicals; Biological control systems -- Periodicals; Molecular biology -- Periodicals; Periodicals; 571.74
• DOI: 10.1016/j.jbior.2020.100758
• Languages: English
• ISSNs: 2212-4926

Abstract

Abstract: The epidermal growth factor receptor (EGFR) interacts with various downstream molecules including phospholipase C (PLC)/protein kinase C (PKC), Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/GSK-3, Jak/STAT and others. Often these pathways are deregulated in human malignancies such as breast cancer. Various therapeutic approaches to inhibit the activity of EGFR family members including small molecule inhibitors and monoclonal antibodies (MoAb) have been developed. A common problem with cancer treatments is the development of drug-resistance. We examined the effects of a conditionally-activated EGFR (v-Erb-B:ER) on the resistance of breast cancer cells to commonly used chemotherapeutic drugs such as doxorubicin, daunorubicin, paclitaxel, cisplatin and 5-flurouracil as well as ionizing radiation (IR). v-Erb-B is similar to the EGFR-variant EGFRvIII, which is expressed in various cancers including breast, brain, prostate. Both v-Erb-B and EGFRvIII encode the EGFR kinase domain but lack key components present in the extracellular domain of EGFR which normally regulate its activity and ligand-dependence. The v-Erb-B oncogene was ligated to the hormone binding domain of the estrogen receptor (ER) which results in regulation of the activity of the v-Erb-ER construct by addition of either estrogen (E2) or 4-hydroxytamoxifen (4HT) to the culture media. Introduction of the v-Erb-B:ER construct into the MCF-7 breast cancer cell line increased the resistance to the cells to various chemotherapeutic drugs, hormonal-based therapeutics and IR. These results point to the important effects that aberrant expression of EGFR kinase domain can have on therapeutic resistance.